For the listed overlapping indications, Inobrodib had a Phase 1/2 clinical program while NXO-001 remained a Development Candidate, giving Inobrodib a development-stage lead for multiple myeloma, but this does not show a clinical outcome advantage. NXO-001 is a selective p300 inhibitor designed to avoid toxicities from targeting both p300 and CBP, with listed indications in prostate cancer, multiple myeloma, and lymphoma. Inobrodib (CCS1477) is an inhibitor of both p300 and CBP under investigation for hematologic malignancies.

TT125-802 is a selective CBP/p300 bromodomain inhibitor under an ongoing first-in-human Phase 1 monotherapy trial in patients with solid tumors. Selective p300 inhibition has remained out of reach because of the high homology between p300 and its paralog CBP.

The collaboration with Calico is a potential growth driver for Nexo Therapeutics' discovery work because it combines Calico's disease-biology expertise with Nexo's target-biology and ligand-discovery capabilities to pursue new small-molecule candidates. Nexo's integrated platform offers a compelling approach to defining pharmacology and enabling the discovery of novel small molecule therapies for historically undruggable or hard-to-drug targets.

Nexo says it works at the intersection of target biology and ligand discovery, and that this collaboration will pair those capabilities with Calico's disease-biology expertise to advance small-molecule candidates not accessible through traditional approaches.

Nexo's investment case combines an existing selective p300 oncology candidate, a covalent-ligand discovery library, and a Calico partnership on challenging disease biology. NXO-001 is a selective p300 inhibitor designed to avoid toxicities associated with targeting p300 and CBP together; its listed indications are prostate cancer, multiple myeloma, and lymphoma, and its stage is Development Candidate. Nexo's CODON library includes more than 12,000 covalent ligands designed with low promiscuity and tuned to access transient cryptic pockets.

Nexo announced its launch Series A financing on July 26, 2023. Calico said it was pleased to partner with Nexo to explore new approaches to targeting challenging disease biology.

Nexo advances hard-to-drug targets toward drug candidates by combining covalent ligand discovery, chemical biology and target-specific pharmacology, using a CODON library of more than 12,000 covalent ligands and integrated PK/PD modeling to guide optimization.

Its selective p300 inhibitor NXO-001, designed to avoid toxicities linked to dual p300/CBP targeting, is a Development Candidate for prostate cancer, multiple myeloma and lymphoma.